EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tumor‐Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development

Keiko Yamamoto iD, Aya Iwase, Hideki Maeda iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Keiko Yamamoto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Regulatory Science, Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Drug Development, Clinical Trials, Phase III as Topic, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in novel therapeutic modalities, such as molecularly targeted agents and immunotherapies, the probability of success in Phase III oncology trials remains low. This study quantitatively characterized success probabilities of Phase III trials in oncology drug development and evaluated the factors associated with trial success. Phase III interventional oncology drug trials registered at ClinicalTrials.gov between 2007 and 2023 with publicly available primary endpoint results were included. Trial success was defined as the achievement of at least one primary endpoint, and tumor‐specific success probabilities were calculated. Multivariable logistic regression analyses were conducted to assess the association between trial success and key trial characteristics. We analyzed 824 trials (358 successful and 466 unsuccessful). Overall success probabilities were comparable between solid tumors and hematologic malignancies, although substantial heterogeneity was observed across solid tumors, with particularly low success probabilities for central nervous system tumors and pancreatic cancer. Multivariable analyses showed that biomarker‐based patient selection, more recently initiated trials, line of therapy, and the number of primary endpoints were associated with trial success. Trials evaluating molecularly targeted therapies and those with short‐term evaluable endpoints showed higher success probabilities, whereas trials evaluating chemotherapy or assessing overall or event‐free survival endpoints showed lower success probabilities. Phase III trial success in oncology is associated with tumor‐specific characteristics and development‐stage factors, including biomarker‐based patient selection and trial design. These results provide quantitative evidence to inform decision‐making and trial design in oncology drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentClinical Trials, Phase III as TopicNeoplasmsAntineoplastic AgentsHumansEndpoint DeterminationProbabilityBiomarkers, TumorPatient SelectionMolecular Targeted TherapyTreatment Outcome

Stichwörter der Autor:innen

biomarker‐based patient selectionclinical trial designoncology drug developmentphase III clinical trialstrial success probability

Substanzen

Antineoplastic AgentsBiomarkers, Tumor

Autor:innen und Institutionen

  • Regulatory Science, Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo, Japan.
  • Genmab K.K., Tokyo, Japan.

ORCID-Profile: Keiko Yamamoto, Hideki Maeda

Zitieren

APA

Yamamoto, K., Iwase, A., & Maeda, H. (2026). Tumor‐Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development. Clinical and Translational Science. https://doi.org/10.1111/cts.70635

Vancouver

Yamamoto K, Iwase A, Maeda H. Tumor‐Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development. Clinical and Translational Science. 2026. doi:10.1111/cts.70635

BibTeX
@article{Yamamoto2026,
  author = {Yamamoto, Keiko and Iwase, Aya and Maeda, Hideki},
  title = {Tumor‐Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70635}
}
Kostenlos starten →